bpc-157 and thymosin beta 4 BPC 157 vs TB 500 — Research Peptide Comparison TB 500 vs BPC 157:

Main Phase (Baseline to Week 26): Study 1 (NCT 00123253) This study randomized 412 HIV-infected patients with lipodystrophy and excess abdominal fat to receive either a 2 mg dose of EGRIFTA (1 mg/vial formulation) (N=273) or placebo (N=137)

It also helps to form myelin sheath to protect nerve cells and conduct nerve impulses, and lowers homocysteine levels thereby reducing the risk of strokes or heart attacks

CNS Effects: Dizziness, nervousness, confusion, or seizures

Its mechanism is purely metabolic: it directly targets lipid metabolism via inhibition of NNMT and restoration of cellular NAD+

These will re-dissolved on gentle warning